FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) > Cancer Cell

Cancer Cell

Cancer Cell patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

04/17/14 - 20140105916 - Human c-fms antigen binding proteins
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages....

04/17/14 - 20140105917 - Frizzled-binding agents and uses thereof
Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using...

04/17/14 - 20140105918 - Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate...

04/17/14 - 20140105919 - Synergistic inhibition of erbb2/erbb3 signal pathways in the treatment of cancer
Methods for treating tumors comprising cells overexpressing ErbB2 or ErbB3 are provided, and comprise inhibiting the biologic activity of one or more of ErbB2 and ErbB3 in the cells and inhibiting the expression or the biologic activity of a constituent of a signal pathway connected with ErbB2 or ErbB3 signaling....

04/10/14 - 20140099332 - Diagnostic assays and kits for detection of folate receptor 1
The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided....

04/03/14 - 20140093521 - Therapeutic dll4 binding proteins
Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or...

03/27/14 - 20140086938 - Methods of inhibiting tumor growth using ttk antagonists
The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like...

03/27/14 - 20140086939 - Compositions and methods for detecting and treating cancer
The invention provides methods for detecting the presence of cancer initiating cells in a tissue, methods for identifying test agent for reducing cancer, and methods for reducing cancer in a subject. The invention's methods are applicable to any cancer, and in particular to liver cancer. The invention also provides the...

03/27/14 - 20140086940 - Herceptin® adjuvant therapy
The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®....

03/20/14 - 20140079720 - Inhibitors of extracellular hsp90
The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion...

02/27/14 - 20140056921 - Hepatocyte growth factor receptor antagonists and uses thereof
Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions,...

02/27/14 - 20140056922 - Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune...

02/13/14 - 20140044739 - Cdim binding proteins and uses thereof
The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin...

02/13/14 - 20140044740 - Diagnostic and therapeutic targets for leukemia
The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and HoxA5 promoter activity....

02/13/14 - 20140044741 - B-type plexin antagonists and uses thereof
The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying...

02/06/14 - 20140037655 - Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors...

01/30/14 - 20140030276 - Cancer immunopotentiating agent containing rankl antagonist
The present invention provides a cancer immunopotentiating agent containing a compound that blocks RANKL action. The present invention relates to a cancer immunopotentiating agent containing a RANKL antagonist such as an anti-RANKL neutralizing antibody as an active ingredient....

12/26/13 - 20130344093 - Anti-egfr antibodies and uses thereof
The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth...

12/12/13 - 20130330362 - Humanized anti-egfr antibody l4-h3 and coding gene thereof
A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is...

11/28/13 - 20130315934 - Methods and compositions for assessing and treating cancer
The invention relates to methods and compositions for identifying mutations associated with cancer, such as melanoma. More particularly, the invention relates to methods and compositions for assessing particular mutations as markers for cancer, such as melanoma. Such methods and compositions allow medical providers to diagnose cancer, such as melanoma, based...

11/21/13 - 20130309253 - Cancer treatment with endothelin receptor antagonists
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are...

11/21/13 - 20130309254 - Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
Described herein is the identification of 68 genes with an elevated frequency of somatic mutations in melanoma. Nine genes were identified that exhibited recurring mutations in melanoma. The TRRAP gene was mutated at nucleotide 2165 (C2165T) in six different melanoma tumor samples. In addition, 16 genes were identified that were...

11/21/13 - 20130309255 - Biomarkers, uses of biomarkers and a method of identifying biomarkers
The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein2, protein transforming growth factor beta induced protein ig-h3, protein asporin, protein tenascin, protein periostin, protein galectin, protein fibronectin, protein prolargin, protein protein-glutamine gamma-glutamyl transferase 2, protein agrin, protein adipocyte enhancer-binding...

11/14/13 - 20130302355 - Novel modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyper-proliferative disorders are provided....

11/14/13 - 20130302356 - Method of treating cancer with dll4 antagonist and chemotherapeutic agent
The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of...

11/07/13 - 20130295118 - Antibodies specific for cll-1
Provided herein are antibodies specific for CLL-1....

11/07/13 - 20130295119 - Folate receptor 1 antibodies and immunoconjugates and uses thereof
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided....

10/31/13 - 20130287798 - Uses of monoclonial antibody 8h9
This invention provides an antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the heavy chain CDR (Complementary Determining Region)1 comprises NYDIN, heavy chain CDR2 comprises WIFPGDGSTQY, heavy chain CDR3 comprises QTTATWFAY, and the light chain CDR1 comprises RASQSISDYLH, light chain CDR2 comprises YASQSIS, and light...

10/24/13 - 20130280277 - Notch1 receptor binding agents and methods of use thereof
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand...

10/24/13 - 20130280278 - Anti-vegfr-3 antibody compositions
The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease....

10/17/13 - 20130273079 - Ultraconserved regions encoding ncrnas
Described herein are methods for differentiate human cancers comprising using one or more transcribed ultraconserved regions (T-UCR) expression profiles where the association between the genomic location of UCRs and the analyzed cancer-related genomic elements is highly statistically significant and comparable to that reported for miRNAs....

10/10/13 - 20130266592 - Companion animal treatments
The invention relates to minimising the progression of cancer in a companion animal using P2X7 immunotherapy....

10/10/13 - 20130266593 - Microvesicle protein for cancer targeting
Microvesicles play essential roles in disease progression. The present invention provides a novel microvesicle membrane protein and application thereof. Disclosed is method comprises phosphorylated CSE1L (cellular apoptosis susceptibility protein)- or CSE1L-binging agents for microvesicle isolation, analysis, or binding for disease diagnosis or treatment....

10/10/13 - 20130266594 - Anti-notch1 antibodies
The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions....

10/03/13 - 20130259877 - Reagents, methods, and kits for the classification of cancer
Reagents, methods, and kits for the classification of cancer that comprise or employ antibodies that bind specific regions of CD43. One method includes contacting tissue with an antibody capable of specifically binding the cytoplasmic tail of CD43, contacting the tissue with an antibody capable of specifically binding the extracellular domain...

10/03/13 - 20130259878 - Antibodies
The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to CDH17 with high affinity. Nucleic acid molecules encoding CDH17 antibodies, expression vectors, host cells and methods for expressing CDH17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CDH17 antibodies are also provided. Methods for...

09/05/13 - 20130230541 - Anti-igf antibodies
Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties...

08/22/13 - 20130216558 - Compositions and methods for treating haematological proliferative disorders of myeloid origin
The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells....

08/22/13 - 20130216559 - Stromal antigen 2 (stag2) compositions and methods
Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines....

08/01/13 - 20130195896 - Compositions and methods for the treatment of a neoplasia
The invention provides methods for the treatments of neoplasia featuring agents that interfere with the expression or activity of a TNFa receptor....

07/25/13 - 20130189285 - Antibodies against ramp3
Isolated antibodies capable of binding a receptor activity modifying protein (RAMP) of CRLR receptor wherein the antibodies are of IgG, IgA or IgM isotype are provided, together with nucleic acid molecules encoding such antibodies, vectors comprising such nucleic acid molecules, host cells comprising such vectors, and methods of making the...

07/11/13 - 20130177578 - Treatment of metastatic breast cancer
The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody....

07/11/13 - 20130177579 - Anti-transferrin receptor antibodies and methods using same
The present disclosure relates to antibodies that recognize a carbohydrate on transferrin receptor expressed by nonhematopoietic tumor or cancer cells and uses thereof....

07/04/13 - 20130171173 - Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf
A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer....

07/04/13 - 20130171174 - Anti-human epidermal growth factor receptor antibody and uses thereof
An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided....

06/27/13 - 20130164309 - Antibodies to the b12-transcobalamin receptor
The present invention provides anti-TCblR antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders....

06/20/13 - 20130156795 - Methods for inhibition of cell proliferation, synergistic transcription modules and uses thereof
The invention provides for methods for treating nervous system cancers in a subject. The invention further provides methods for treating nervous system tumor cell invasion, migration, proliferation, and angiogenesis associated with nervous system tumors....

06/13/13 - 20130149319 - Anticancer composition
Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by...

06/13/13 - 20130149320 - Asf1b as a prognosis marker and therapeutic target in human cancer
The present invention provides a prognostic marker in human cancer, Asf1b, a high expression thereof being associated with a poor prognosis. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy. Finally, the present invention provides a new therapeutic target for...

06/06/13 - 20130142812 - Antibody and use thereof
A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in...

05/30/13 - 20130136755 - Mlk4 gene, a new diagnostic and prognostic marker in cancers
An in vitro diagnostic method for determining invasive potential of cancer comprising measuring MLK4 gene expression in a cancer cell sample, wherein MLK4 gene overexpression is indicative of an invasive cancer, preferably a colorectal, bladder, breast, gastric, melanoma, lung, ovary or GMB cancer....